Description

BridgeBio Pharma’s ATTRuby Breakthrough: 392% Growth Signals A Commercial Reset!

BridgeBio Pharma delivered strong first-quarter 2026 financial results driven primarily by significant growth in sales of Attruby, its treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Net product revenue for Attruby reached $180.6 million, marking a 24% increase from the prior quarter and a 392% increase year-over-year. The company emphasized that growth was fueled by expanding new patient starts, first-line share gains, and effective commercial strategies, including high patient adherence and limited insurance authorization issues aided by favorable Part D coverage. Attruby’s clinical differentiation, supported by emerging real-world evidence studies suggesting superiority over Pfizer’s tafamidis in outcomes such as reduced mortality and kidney injury incidence, was highlighted as a key factor underpinning growing market share and physician adoption. Beyond Attruby, BridgeBio is advancing three other late-stage pipeline candidates targeting rare diseases: LGMD2I, ADH1, and achondroplasia.